These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33378962)

  • 1. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
    Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
    Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model.
    Yang CY; Lin CK; Hsieh CC; Tsao CH; Lin CS; Peng B; Chen YT; Ting CC; Chang WC; Lin GJ; Sytwu HK; Chen YW
    Head Neck; 2019 May; 41(5):1260-1269. PubMed ID: 30537218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines.
    Zhang L; Yu JS
    J Neurooncol; 2019 Jul; 143(3):429-436. PubMed ID: 31152305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
    Wu T; Tang C; Tao R; Yong X; Jiang Q; Feng C
    Front Immunol; 2021; 12():693881. PubMed ID: 34552581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Immunomodulatory Effect of Triptolide on Mesenchymal Stromal Cells.
    He H; Takahashi A; Mukai T; Hori A; Narita M; Tojo A; Yang T; Nagamura-Inoue T
    Front Immunol; 2021; 12():686356. PubMed ID: 34484183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells.
    Wudtiwai B; Makeudom A; Krisanaprakornkit S; Pothacharoen P; Kongtawelert P
    Molecules; 2021 Sep; 26(17):. PubMed ID: 34500779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptolide exerts anti-tumor effect on oral cancer and KB cells in vitro and in vivo.
    Chen YW; Lin GJ; Chia WT; Lin CK; Chuang YP; Sytwu HK
    Oral Oncol; 2009 Jul; 45(7):562-8. PubMed ID: 19359213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
    Gao A; Pan X; Yang X; Lin Z
    Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide represses oral cancer cell proliferation, invasion, migration, and angiogenesis in co-inoculation with U937 cells.
    Yang CY; Lin CK; Lin GJ; Hsieh CC; Huang SH; Ma KH; Shieh YS; Sytwu HK; Chen YW
    Clin Oral Investig; 2017 Jan; 21(1):419-427. PubMed ID: 27073100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
    Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
    Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
    Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
    Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brusatol improves the efficacy of an anti-mouse-PD-1 antibody via inhibiting programmed cell death 1 ligand 1 expression in a murine head and neck squamous cell carcinoma model.
    Wu Y; Zhang G; Yin P; Wen J; Su Y; Zhang X
    Arch Oral Biol; 2024 Oct; 166():106043. PubMed ID: 38968906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer.
    Jang JY; Lee BS; Huang M; Seo C; Choi JH; Shin YS; Woo HG; Kim CH
    Mol Oncol; 2024 Aug; 18(8):1923-1939. PubMed ID: 38511232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
    Wu Q; Zhao Y; Sun Y; Yan X; Wang P
    Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
    Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
    Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
    Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
    Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y
    Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.